KIT expression in chromophobe renal cell carcinoma -: Comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms
KIT expression in chromophobe renal cell carcinoma -: Comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms
复制标题
DOI：
10.1097/00000478-200405000-00017
复制
发表时间：
2004-05-01
影响因子：
5.6
通讯作者：
Mallofré, C
中科院分区：
文献类型：
--
作者：
Petit, A;Castillo, M;Mallofré, C
c-Kit在嫌色细胞肾细胞癌（ChRCC）的过度表达已被描述的比较基因表达分析，并已提出作为一个可能的具体标志，这种肿瘤。我们研究的目的是建立其在一个大系列的ChRCC的免疫组化表达，并将其与其他肾肿瘤进行比较。在我们的研究中，KIT的免疫组化特征进行了87例肾肿瘤，包括25例ChRCC，13例肾嗜酸细胞瘤，和39例肾细胞癌（21例常规RCC [CRCC]，8例CRCC与颗粒细胞分化，和10例乳头状RCC [PRCC]）。88%的ChRCC和71%的嗜酸细胞瘤表达KIT，而研究的其他类型的RCC均为阴性。KIT在ChRCC和嗜酸细胞瘤中的免疫组化表达的意义尚不清楚，但其免疫组化染色似乎有助于区分ChRCC与PRCC，CRCC及其颗粒细胞变体。此外，我们的研究结果支持目前认为嗜酸细胞瘤和ChRCC之间存在组织病理学关系的模型。最后，应该确定KIT是否在ChRCC和嗜酸细胞瘤的肿瘤发生中起作用，以及KIT抑制剂STI-571的靶向治疗是否在具有转移性扩展或复发的ChRCC的特殊病例中有效。
The overexpression of c-Kit in chromophobe renal cell carcinoma (ChRCC) has been described by comparative gene expression analyses and has been proposed as a possible specific hallmark of this neoplasm. The aim of our study was to establish its immunohistochemical expression in a large series of ChRCC and to compare it with other renal neoplasms. In our study, immunohistochemical characterization of KIT was performed in 87 renal neoplasms including 25 cases of ChRCC, 13 cases of renal oncocytoma, and 39 renal cell carcinomas (21 cases of conventional RCC [CRCC], 8 cases of CRCC with granular cell differentiation, and 10 cases of papillary RCC [PRCC]). Eighty-eight percent ChRCC and 71% oncocytomas showed immunohistochemical expression of KIT, while the other types of RCC studied were all negative. The meaning of immunohistochemical expression of KIT in ChRCC and oncocytomas is still unknown, but its immunohistochemical staining appears to be useful in distinguishing ChRCC from PRCC, CRCC, and its granular cell variant. Moreover, our findings support current models that consider that there is a histopathogenic relationship between oncocytoma and ChRCC. Finally, it should be determined whether KIT plays a role in the tumorigenesis of ChRCC and oncocytoma and whether targeted therapy with STI-571, an inhibitor of KIT, could be effective in exceptional cases of ChRCC with metastatic extension or recurrence.